Suven Life gets patent from New Zealand for neurological drug
New Delhi: Drug firm Suven Life Sciences has received a patent from New Zealand for a drug used for the treatment of neurodegenerative diseases.
In a BSE filing today, Suven Life said it has been granted "one product patent from New Zealand corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases".
The patents are valid till 2034, the company added.
Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd